A phase II study of antiangiogenic therapy (Apatinib) plus chemotherapy as second-line treatment in advanced small cell lung cancer.

Yinghui XuXu WangChao SunZhiru GaoHua HeShi QiuYe GuoXiaohui MaJunya SongKewei Ma

Published in: Cancer medicine (2022)

Antiangiogenic therapy plus chemotherapy had encouraging efficacy in advanced SCLC patients, which provides an insight into the current status of second-line therapy in SCLC.

Keyphrases

small cell lung cancer
phase ii study
locally advanced
end stage renal disease
current status
newly diagnosed
ejection fraction
open label
randomized controlled trial
radiation therapy
peritoneal dialysis
cell therapy
placebo controlled